Approaches, Progress, and Challenges to Hepatitis C Vaccine Development

Justin Bailey, Eleanor Barnes, Andrea Cox

Research output: Contribution to journalArticle

Abstract

Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.

Original languageEnglish (US)
Pages (from-to)418-430
Number of pages13
JournalGastroenterology
Volume156
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatitis C
Hepacivirus
Vaccines
Virus Diseases
Viral Core Proteins
Infection
Healthy Volunteers
Viruses
Antigens
Proteins

Keywords

  • HCV
  • Prophylactic Vaccination
  • Vaccines
  • Viral Hepatitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. / Bailey, Justin; Barnes, Eleanor; Cox, Andrea.

In: Gastroenterology, Vol. 156, No. 2, 01.01.2019, p. 418-430.

Research output: Contribution to journalArticle

@article{0924ee14f6a140d38f5bbf902ea7e780,
title = "Approaches, Progress, and Challenges to Hepatitis C Vaccine Development",
abstract = "Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90{\%} reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.",
keywords = "HCV, Prophylactic Vaccination, Vaccines, Viral Hepatitis",
author = "Justin Bailey and Eleanor Barnes and Andrea Cox",
year = "2019",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2018.08.060",
language = "English (US)",
volume = "156",
pages = "418--430",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Approaches, Progress, and Challenges to Hepatitis C Vaccine Development

AU - Bailey, Justin

AU - Barnes, Eleanor

AU - Cox, Andrea

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.

AB - Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.

KW - HCV

KW - Prophylactic Vaccination

KW - Vaccines

KW - Viral Hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85060095595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060095595&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.08.060

DO - 10.1053/j.gastro.2018.08.060

M3 - Article

VL - 156

SP - 418

EP - 430

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -